破发股汇宇制药二股东拟被动减持 2021年上市募24.7亿

Core Viewpoint - The announcement reveals that Huang Qianyi, a major shareholder of Huili Pharmaceutical, will passively reduce his shareholding due to a court's enforcement ruling, which mandates the forced sale of 1,300,000 shares [1][2] Group 1: Shareholder Reduction Plan - Huang Qianyi plans to reduce his holdings from February 3, 2026, to May 3, 2026, through centralized bidding, with a potential reduction of up to 1,300,000 shares, representing 0% to 0.307% of the company's total share capital [1] - The reduction is a result of judicial enforcement, and the shares involved are all unrestricted circulating shares [1] Group 2: Shareholder Information - As of the announcement date, Huang Qianyi holds 27,219,439 shares, accounting for 6.426% of Huili Pharmaceutical's total share capital [1] - Huang Qianyi is identified as the second-largest shareholder of Huili Pharmaceutical [2] Group 3: Company Background - Huili Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [2] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs [3] - The company plans to use the raised funds for the construction of an EU-standard injection production base and an innovative drug research institute, as well as to supplement working capital [3]